Anthem Biosciences

Anthem Biosciences is a leading Indian Contract Research, Development and Manufacturing Organization (CRDMO) that describes itself as a 'Contract Research and Innovation Service Provider' (CRISP). Founded in 2007, the company provides end-to-end drug discovery, development, and manufacturing services for both small molecules and biologics (large molecules). Anthem operates several state-of-the-art facilities in Bangalore, serving a global clientele that includes major pharmaceutical companies and emerging biotechs. The company is distinguished by its 'China-plus-one' strategy, having built a supply chain with minimal dependence on Chinese raw materials. Following its successful IPO in July 2025, Anthem has significantly expanded its manufacturing capacity, particularly in peptides, oligonucleotides, and large-scale fermentation.